Apealea

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
R/0017	Renewal of the marketing authorisation.	20/07/2023	11/09/2023	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Apealea in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IA/0018	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the	03/04/2023	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	finished product, including quality control sites (excluding manufacturer for batch release)				
IB/0016	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	08/11/2022	n/a		
IB/0015	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	09/09/2022	24/03/2023	SmPC and PL	
PSUSA/2264/ 202112	Periodic Safety Update EU Single assessment - paclitaxel	01/09/2022	n/a		PRAC Recommendation - maintenance
IAIN/0013	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	11/03/2022	24/03/2023	Annex II and PL	
T/0012	Transfer of Marketing Authorisation	04/11/2021	09/12/2021	SmPC, Labelling and PL	
IA/0011	A.7 - Administrative change - Deletion of manufacturing sites	16/03/2021	n/a		
IA/0010/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	20/11/2020	n/a		

	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites				
IB/0009/G	This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	28/05/2020	n/a		
IA/0008/G	This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its	10/04/2020	n/a		

	corresponding test method B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IAIN/0007	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	18/02/2020	n/a		
IB/0006	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale	04/02/2020	13/08/2020	SmPC	

	(supported by real time data)				
PSUSA/2264/ 201812	Periodic Safety Update EU Single assessment - paclitaxel	25/07/2019	01/10/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2264/201812.
II/0003/G	This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.c.4.b - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient excipient - The specifications are affected or there is a change in physico-chemical properties of the excipient which may affect the quality of the FP B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	19/09/2019	13/08/2020	SmPC and PL	

	procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation				
IA/0004	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	02/04/2019	n/a		
II/0001	Update of section 5.1 of the SmPC in order to present post-hoc analyses of efficacy results for patients with first relapse in accordance with the approved indication. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor typographical errors in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/03/2019	01/10/2019	SmPC	In the ITT population of the pivotal efficacy study, the hazard ratios for PFS in the subgroups of patients with first relapse and second relapse were 0.80 (95% CI: 0.66;0.97) and 1.04 (95% CI: 0.74;1.47), respectively. The hazard ratios for OS in patients with first and second relapse were 0.98 (95% CI: 0.79;1.21) and 1.18 (95% CI: 0.79;1.75), respectively. Thus, the results in the subgroup of patients with first relapse are consistent with the results in the overall population and in addition, there was an indication of PFS benefit for Apealea. For more information, please refer to the Summary of Product Characteristics.
IAIN/0002/G	This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished	04/03/2019	n/a		

	product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)				